Download PDF

1. Company Snapshot

1.a. Company Description

BridgeBio Pharma, Inc.engages in the discovery, development, and delivery of various medicines for genetic diseases.The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.


Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones.In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases.


BridgeBio Pharma, Inc.has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc.The company was founded in 2015 and is headquartered in Palo Alto, California.

Show Full description

1.b. Last Insights on BBIO

BridgeBio Pharma, Inc.'s recent performance was negatively impacted by several factors. The company's CFO, Thomas Trimarchi, sold 13,600 shares of the company's stock, raising concerns about insider sentiment. Additionally, BIT Capital GmbH reduced its holdings in BridgeBio Pharma by 94.0%, selling 16,504 shares during the quarter. Furthermore, the company's stock pulled back sharply from its Jan. 22 record high after Pfizer withdrew a tafamidis patent in the European Union. Despite a "Moderate Buy" rating from analysts, these developments may have contributed to downward pressure.

1.c. Company Highlights

2. BridgeBio Pharma's Q4 2025 Earnings: A Strong Year for Atruby

BridgeBio Pharma's financial results for the full year 2025 showed a significant increase in total revenues to $502.1 million compared to $221.9 million in 2024, driven primarily by a $359.5 million increase in net product revenue for Atruvio. The company's cash position ended the year at $587.5 million in cash, cash equivalents, and marketable securities. The actual EPS came out at '-1.00697', missing estimates at '-0.75'. Analysts estimate next year's revenue growth at 72.0%.

Publication Date: Feb -25

📋 Highlights
  • Atruby Revenue Growth:: 35% quarter-over-quarter net product revenue growth in Q4 2025, reaching $146 million, with $362.4 million annual total.
  • Phase 3 Program Success:: Positive top-line results for 3 late-stage assets (Encalarec NADH1 BBP-418, infigratinib, and infigratinib for achondroplasia), including 2.1 cm/year AHV improvement in infigratinib.
  • Cash Position & Burn:: $587.5 million cash reserves as of year-end 2025, with cash burn declining Q4 2025 and projected stability through 2026.
  • Future Profitability:: Four post-Phase 3 assets expected to generate >$600 million in profit by 2028, with cash generation starting late 2027.
  • ATTR Cardiomyopathy Momentum:: 7,804 new patient starts in Q4 2025, with 1,856 unique prescribers, driven by Atruvio’s near-complete TTR stabilizer differentiation.

Revenue Growth and Cash Position

The company's total revenues for the fourth quarter were $154.2 million, consisting of $146 million of Atruvio net product revenue, $5.3 million of royalty revenue, and $2.9 million of license and service revenue. The cash position is further bolstered by the issuance of $632.5 million aggregate principal amount of 2033 convertible notes in January 2026, providing significant cash runway to support the transition into a diversified late-stage multiproduct business.

Valuation Metrics

Looking at the valuation metrics, the company's P/S Ratio stands at 36.33, indicating a relatively high revenue multiple. The EV/EBITDA ratio is -21.66, suggesting that the company's enterprise value is not justified by its current EBITDA. The ROE is 38.94%, indicating a relatively strong return on equity. The Net Debt / EBITDA ratio is 0.96, suggesting a manageable debt burden.

Commercial Momentum and Pipeline

Atruvio continues to show consistent growth, driven by its differentiated profile as the only near-complete stabilizer on the market. The company attributes this success to its field team, strong data, and discipline in focusing on what's important for patients and HCPs. As Matt Outten stated, "Atruvio is accelerating growth at a significantly faster rate versus previous quarters, while the competition lags behind." The company's pipeline is also progressing well, with positive top-line Phase 3 results for Encalarec NADH1 BBP-418 in LGMD2I and positive top-line data for infigratinib in achondroplasia.

Future Prospects

The company's focus continues to be making sure the drug products registered successful Phase 3s are approved and launched correctly. With a strong commercial momentum and a promising pipeline, BridgeBio Pharma is well-positioned for future growth. The company's guidance on cash burn and expected increases in Etrubee revenue provide a positive outlook for the company's financials.

3. NewsRoom

Card image cap

BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates

Feb -25

Source: zacks.com

Card image cap

BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript

Feb -25

Source: seekingalpha.com

Card image cap

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

Feb -24

Source: globenewswire.com

Card image cap

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 28,053 Shares

Feb -24

Source: defenseworld.net

Card image cap

BridgeBio to Participate in March Investor Conferences

Feb -23

Source: globenewswire.com

Card image cap

Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?

Feb -22

Source: feeds.benzinga.com

Card image cap

Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

Feb -20

Source: defenseworld.net

Card image cap

BIT Capital GmbH Reduces Holdings in BridgeBio Pharma, Inc. $BBIO

Feb -20

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Transformative Medicines

Expected Growth: 10.43%

Transformative Medicines from BridgeBio Pharma, Inc. is driven by its innovative gene therapy pipeline, strong partnerships, and increasing demand for rare disease treatments. The company's focus on genetic diseases with high unmet needs, such as achondroplasia and Canavan disease, positions it for continued growth.

7. Detailed Products

BBP-831

BBP-831 is a small molecule inhibitor of the A2a receptor, a key regulator of inflammation and immune response. It is being developed as a potential treatment for various inflammatory diseases.

ENC-001

ENC-001 is a gene therapy designed to treat congenital erythropoietic porphyria (CEP), a rare and debilitating genetic disorder.

BBP-815

BBP-815 is a small molecule inhibitor of the PI3K delta enzyme, a key regulator of immune cell function. It is being developed as a potential treatment for various autoimmune diseases.

BBP-924

BBP-924 is a small molecule inhibitor of the SHP2 enzyme, a key regulator of cell signaling pathways. It is being developed as a potential treatment for various cancers.

BBP-398

BBP-398 is a gene therapy designed to treat Canavan disease, a rare and debilitating genetic disorder.

8. BridgeBio Pharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

BridgeBio Pharma, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.

Bargaining Power Of Customers

BridgeBio Pharma, Inc. has a low bargaining power of customers due to the lack of concentration in the buyer's market and the high switching costs.

Bargaining Power Of Suppliers

BridgeBio Pharma, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers and the moderate switching costs.

Threat Of New Entrants

BridgeBio Pharma, Inc. has a high threat of new entrants due to the low barriers to entry and the high growth potential in the biotech industry.

Intensity Of Rivalry

BridgeBio Pharma, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 451.23%
Debt Cost 4.21%
Equity Weight -351.23%
Equity Cost 9.33%
WACC -13.76%
Leverage -128.47%

11. Quality Control: BridgeBio Pharma, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
BridgeBio Pharma

A-Score: 5.3/10

Value: 8.0

Growth: 5.1

Quality: 5.9

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Krystal Biotech

A-Score: 5.1/10

Value: 0.8

Growth: 9.8

Quality: 8.9

Yield: 0.0

Momentum: 7.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
IDEAYA Biosciences

A-Score: 4.6/10

Value: 6.7

Growth: 2.9

Quality: 5.1

Yield: 0.0

Momentum: 9.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Alnylam Pharmaceuticals

A-Score: 4.5/10

Value: 0.0

Growth: 7.8

Quality: 4.7

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Insmed

A-Score: 4.4/10

Value: 6.0

Growth: 3.3

Quality: 4.0

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Bio-Techne

A-Score: 3.5/10

Value: 0.9

Growth: 4.2

Quality: 6.3

Yield: 1.0

Momentum: 3.5

Volatility: 5.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

43.6$

Current Price

64.53$

Potential

-32.43%

Expected Cash-Flows